Hepatic Hemodynamics and Portal Flow Modulation: The A2ALL Experience

Transplantation. 2017 Oct;101(10):2375-2384. doi: 10.1097/TP.0000000000001823.

Abstract

Objective: A principal aim of the Adult-to-Adult Living Donor Liver Transplantation Cohort Study was to study hepatic blood flow and effect of portal flow modulation on graft outcomes in the setting of increasing use of smaller and left lobe grafts.

Methods: Recipients of 274 living donor liver transplant were enrolled in the Adult-to-Adult Living Donor Liver Transplantation Cohort Study, including 233 (85.0%) right lobes, 40 (14.6%) left lobes, and 1 (0.5%) left lateral section. Hepatic hemodynamics were recorded after reperfusion. A total of 57 portal flow modulations were performed on 52 subjects.

Results: Modulation lowered portal pressure in 68% of subjects with inconsistent effects on hepatic arterial and portal flow. A higher rate of graft dysfunction was observed in modulated vs. unmodulated subjects (31% vs. 18%; P = 0.03); however, graft survival in modulated subjects was not different from unmodulated subjects at 3 years.

Conclusions: These results suggest the need for a study using a prespecified portal flow modulation protocol with defined indications to better define the effects of these interventions.

Trial registration: ClinicalTrials.gov NCT01619475.

Publication types

  • Multicenter Study
  • Observational Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Adult
  • Aged
  • Blood Flow Velocity
  • Female
  • Graft Survival
  • Hemodynamics*
  • Humans
  • Ligation
  • Liver / blood supply*
  • Liver Circulation*
  • Liver Transplantation / adverse effects
  • Liver Transplantation / methods*
  • Living Donors*
  • Male
  • Middle Aged
  • Ontario
  • Organ Size
  • Portal Pressure
  • Portal Vein / physiopathology
  • Portal Vein / surgery*
  • Portasystemic Shunt, Surgical*
  • Prospective Studies
  • Regional Blood Flow
  • Splenectomy
  • Time Factors
  • Treatment Outcome
  • United States

Associated data

  • ClinicalTrials.gov/NCT01619475